Morgan Woods
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Neuropeptides and Animal Physiology, Antibiotics Pharmacokinetics and Efficacy, Urinary Bladder and Prostate Research, Diabetes Treatment and Management, Receptor Mechanisms and Signaling
Most-Cited Works
- → EFFICACY OF THE β3-ADRENERGIC RECEPTOR AGONIST CL-316243 ON EXPERIMENTAL BLADDER HYPERREFLEXIA AND DETRUSOR INSTABILITY IN THE RAT(2001)112 cited
- → Design and SAR of Novel Potassium Channel Openers Targeted for Urge Urinary Incontinence. 1. N-Cyanoguanidine Bioisosteres Possessing in Vivo Bladder Selectivity(2000)79 cited
- → Structure-activity relationships in the 2-arylcarbapenem series. Synthesis of 1-methyl-2-arylcarbapenems(1987)74 cited
- → Design and SAR of Novel Potassium Channel Openers Targeted for Urge Urinary Incontinence. 2. Selective and Potent Benzylamino Cyclobutenediones(2000)53 cited
- → Comparison of the Potassium Channel Openers, WAY-133537, ZD6169, and Celikalim on Isolated Bladder Tissue and In Vivo Bladder Instability in Rat(1999)49 cited
- → Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type 2 diabetes(2011)43 cited
- → Synthesis of milbemycins from avermectins(1983)25 cited
- → Modification of natural products to improve their biological properties(1987)16 cited
- → Design of Potent and Orally Active GPR119 Agonists for the Treatment of Type II Diabetes(2015)13 cited
- → Discovery of phenyl acetamides as potent and selective GPR119 agonists(2017)12 cited